

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

×

The Effects of Traditional Chinese Exercise on Cardiac Rehabilitation After Percutaneous Coronary Intervention : Study Protocol for Network Meta-analysis of Randomized Controlled Trials

Journal:	BMJ Open
Manuscript ID	bmjopen-2018-023096
Article Type:	Protocol
Date Submitted by the Author:	25-Mar-2018
Complete List of Authors:	Luo, Chuanjin; First Affiliated Hospital of Guangzhou University of Chinese Medicine, Department of Cardiovascular Disease Wen, Junmao; Guangzhou University of Chinese Medicine Sun, Weipeng; Guangzhou University of Chinese Medicine Li, Ting; Guangzhou University of Chinese Medicine Yu, Xiaojiang; First Affiliated Hospital of Guangzhou University of Chinese Medicine, Department of Rehabilitation Center Zhang, Tian; Guangzhou University of Chinese Medicine Zhou, Xiaoqi; Guangzhou University of Chinese Medicine Wu, Wei; First Affiliated Hospital of Guangzhou University of Chinese Medicine, Department of Candgzhou University of Chinese Medicine, Department of Cardiovascular Disease Li, Rong;
Keywords:	Traditional Chinese Exercise, Cardiac Rehabilitation, Coronary heart disease < CARDIOLOGY



The Effects of Traditional Chinese Exercise on Cardiac Rehabilitation After Percutaneous Coronary Intervention: Study Protocol for Network Meta-analysis of Randomized Controlled Trials

Authors

Chuanjin Luo¹, Junmao Wen², Weipeng Sun², Ting Li², Xiaojiang Yu³, Tian Zhang²,

Xiaoqi Zhou¹, Wei Wu¹, Rong Li^{1*}

¹Department of Cardiovascular Disease, First Affiliated Hospital of Guangzhou

University of Chinese Medicine, Guangzhou, China

²Guangzhou University of Chinese Medicine, Guangzhou, China

³Department of Rehabilitation Center, First Affiliated Hospital of Guangzhou

University of Chinese Medicine, Guangzhou, China

Corresponding author

Professor Rong Li

Email: 256298797@qq.com

Tel: 020-36591357

Present address

Guangzhou University of Chinese Medicine, No. 12, Ji Chang Road, Baiyun District,

Guangzhou 510405, China

BMJ Open: first published as 10.1136/bmjopen-2018-023096 on 9 February 2019. Downloaded from http://bmjopen.bmj.com/ on June 10, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

ABSTRACT

Introduction: Coronary heart disease (CHD) is the most common cause of death worldwide. Percutaneous coronary intervention (PCI) has been shown to reduce mortality in patients with CHD. However, there are still recurrences of cardiovascular events after PCI. Cardiac rehabilitation (CR) in patients with established CHD is associated with reductions in cardiovascular mortality and hospital admissions, as well as improved quality of life. More and more clinical trials suggest that traditional Chinese exercise (TCE) plays a positive role in patients post-PCI.

Objective: The primary purposes of the current study are to conduct a network meta-analysis of randomized trials to determine the effects of TCE in patients after PCI, and to separately compare the effects of tai chi, baduanjin and yijinjing on cardiac rehabilitation after PCI.

Methods and analysis: Studies will be retrieved from the following databases: PubMed, Embase, Cochrane Library, Chinese National Knowledge Infrastructure, Wanfang Data, Chinese BioMedical Database and Chinese Science and Technology Periodicals Database, from inception to February 2018. We will include RCTs that are related to the effects of TCE therapies in patients after PCI. The primary outcomes will be all-cause mortality, revascularisations, health-related quality of life (HRQL), and hospitalisations. Two reviewers will independently select eligible articles. For each included article, two reviewers will independently extract the data and assess the risk of bias by using the Cochrane risk of bias tool. Bayesian network meta-analyses will be conducted to pool all treatment effects. The ranking probabilities for the optimal intervention of various treatments (tai chi, baduanjin or yijinjing) will be estimated by the mean ranks and surface under the cumulative ranking curve (SUCRA). The Grading of Recommendations Assessment, Development and Evaluation System will be utilized to assess the quality of evidence.

Ethics and dissemination: The results will be disseminated through peer-reviewed publications. They will provide consolidated evidence to inform clinicians on the potential functions of TCE in CR, and to provide reliable evidence for the application of TCE.

Trial registration number: CRD42018088415

Strengths and limitations of this study

- This is the first systematic review to use network meta-analysis to compare various forms of traditional Chinese exercise.
- This is the first systematic review to compare the effects of baduanjin, vijinjing and tai chi on cardiac rehabilitation post-PCI.
- This study will assess the effects of TCEs and their safety regarding cardiac rehabilitation after PCI.
- The study will use the Grading of Recommendations Assessment, Development and Evaluation System to further assess the quality of the evidence.
- Due to the changes in the frequency and duration of treatment, there may be clinical heterogeneity.

BMJ Open: first published as 10.1136/bmjopen-2018-023096 on 9 February 2019. Downloaded from http://bmjopen.bmj.com/ on June 10, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

INTRODUCTION

Description of the condition

Coronary heart disease (CHD), also known as coronary artery disease (CAD), is the most common cause of death worldwide, causing 7.4 million deaths in 2013, accounting for one-third of all deaths globally (WHO 2014)¹. In addition to the requisite medical therapy, mechanical revascularization with coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) is needed for patients with CHD. PCI has been shown to reduce mortality in patients with CHD². During follow-up, however, the benefits of PCI surgery still carry significant risks of coronary spasm, endothelial cell injury, recurrent ischemia, and even restenosis or thrombus³⁻⁵. Numerous guidelines endorse the necessities of cardiac rehabilitation (CR), which is recommended for patients with chronic stable angina, acute coronary syndromes or for patients post-PCI surgery⁶⁻¹¹. Combined with routine therapy, exercise-based CR, which has been recommended by American Heart Association (AHA) guidelines¹², is a safe option, and is preferred by both clinicians and patients after PCI. It has been reported that light to moderate intensity physical activity can reduce coronary heart disease mortality¹³.

Description of the intervention

For centuries, traditional Chinese exercise (TCE) (Figure 1), including tai chi, baduanjin and yijinjing, has been widely practiced in China for both preventive and therapeutic purposes. Considered to be a low-risk, promising intervention that is used widely in the prevention of cardiovascular disease nowadays, TCEs are easy to master in a short time and have few physical demands¹⁴. Regardless of previous exercise experience or aerobic capacity, the exercise intensity of TCE is suited for persons of all ages. Moreover, TCE requires no expensive equipment and can be performed either individually or in groups. Most existing systematic reviews have focused on specific forms of TCE, such as tai chi or baduanjin¹⁵⁻¹⁷. Whether TCE has positive clinical effects on patients with CHD after PCI, however, remains unclear.

Therefore, we will conduct the present network meta-analysis to explore the following points (Figure 2): to explore whether TCE affects the primary endpoint events of cardiac death, recurrence of MI, repeated PCI, and restenosis after PCI; to determine whether TCE could be an effective method for improving secondary endpoint measures such as quality of life (QoL), physical functions and symptoms, after PCI; to separately compare the effects of Tai chi, Baduanjin and Yijinjing on patients post-PCI.

METHODS AND ANALYSIS

Registration

This protocol has been developed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement. It has also been registered with the International Prospective Register of Systematic Reviews (registration number CRD42018088415).¹⁸

Eligibility criteria

Study type

We will include randomised controlled trials that investigate the effects of three different traditional Chinese exercise therapies (Tai chi, Baduanjin and Yijinjing) on CR following PCI. The following study designs or publication types will be excluded: (1) non-clinical research literature, such as animal experiments, reviews or case

reports; (2) duplicate publications; (3) literature with incomplete data, the study of chaos; (4) studies which lack primary outcome measures.

Participants

This network-analysis will include patients with coronary heart disease who have received TCE intervention after PCI.

Patient and Public Involvement

patients and public will not be involved.

Interventions

We plan to include the following TCE therapies: tai chi, baduanjin and yijinjing, and patients who have received TCE interventions either alone or in combination with appropriate training.

Outcomes

The primary outcomes will include: (1) all-cause mortality; (2) revascularisations (CABG or PTCA); (3) generic instrument of HRQL, such as SF-36 health survey scores; (4) hospitalisations: hospital readmission dates.

The secondary outcomes will include: (1) BNP; (2) blood lipid indexes, such as TC,

TG, LDL-C and HDL-C; (3) Echocardiography; (4) Adverse events.

Search strategy

We will retrieve articles from the following databases: PubMed, Embase, Cochrane Library, Chinese National Knowledge Infrastructure, Wanfang Data, Chinese BioMedical Database and Chinese Science and Technology Periodicals Database. We anticipate that the databases will be searched from their inception to February 2018. The search strategy in PubMed database is as follows, ((((((((((Tai Ji Quan) OR Tai chi) OR Tai ji) OR Taijiquan) OR Baduanjin) OR Baduanjin exercise) OR eight section brocades) OR Yi Jinjing) OR Yijinjing) OR Yijinjing exercise)) AND Heart OR ((((((((((Coronary Disease) Coronary artery atherosclerosis heart disease) OR CHD) OR Acute coronary syndrome) OR ACS) OR Acute myocardial infarction) OR AMI) OR Heart failure) OR HF) OR percutaneous coronary intervention) OR PCI). The search strategy for PubMed is shown in Table 1.

The search strategy will be developed by two reviewers (Weipeng Sun and Ting Li) who will independently review the full texts of potentially eligible studies. Discrepancies in the meta-analysis will be discussed and settled by a third reviewer. We will use a preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart to discern, filter, and eliminate selected articles. We will express the study selection process with a PRISMA flow chart (http://www.prisma-statement.org) (Figure 3).

Data collection process

All titles and abstracts of potential trials will be retrieved and organised by two authors (Weipeng Sun and Ting Li) in Endnote X7. Duplicate records will be excluded. The database will then be copied and provided to the first author for duplicate screening. Any disagreements between the two authors will be resolved by discussion with the whole team at a regular meeting. We will allocate the trials to the following five groups: inclusion group, non-patient group, intervention group, outcome group and awaiting group. For this project, Microsoft Excel will be used for preliminary data collection. Four spreadsheets including general information (author list, publication year, and journal), characteristics of the included trials (diagnostic criteria, age range, study drugs, and dose range), risk of bias assessed using the Cochrane risk of bias tool¹⁹ and outcome data extraction (number of participants who responded to treatment and the number who dropped out during the treatment), will be represented in the table. Relevant original data will be submitted as attachments.

Quality assessment

The methodological quality of the eligible studies, concealment allocation, covering randomisation, blinding and other biases will be evaluated by two authors (Tian Zhang, Xiaoqi Zhou) according to the Cochrane revised tool for Risk of Bias²⁰. Particular attention will be paid to the adequacy of random allocation concealment and blinding due to the potential failure of inadequate concealment in the randomisation test. Considering the diagnostic criteria, the sample size calculation method, reporting of withdrawals and follow-up, any other sources of bias will be cautiously assessed. Another two authors (Xiaojiang Yu, Wei Wu) will assess the

quality of evidence using the GRADE framework, covering study limitations, inconsistency, indirectness, imprecision and publication bias. The complete assessment procedures are as follows²¹: (1) offer direct and indirect effect estimates; (2) assess the quality of direct and indirect estimates; (3) present the results of the network meta-analysis; (4) assess the quality of the network meta-analysis effect estimates.

Dealing with missing data

We will initially contact both senior and/or corresponding author to obtain any missing data. If no one responds, the following approaches will be used to estimate the missing data. Instead of providing the mean and SD, the number of responding patients employing a validated imputation method will be calculated for studies failing to report the patients' numbers after treatment. We will also try to estimate from graphs if possible. The reason for exclusion of the available data will be excluded, but the reason for exclusion will be reported. BMJ Open: first published as 10.1136/bmjopen-2018-023096 on 9 February 2019. Downloaded from http://bmjopen.bmj.com/ on June 10, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Network meta-analysis

We will use the Markov Chain Monte Carlo algorithm (MCMC) by applying WinBUGS 1.4.3 to conduct the network meta-analysis (NMA) in a Bayesian hierarchical framework. The magnitude of heterogeneity variance will be used to investigate the statistical heterogeneity of all of the NMAs. If direct evidence is feasible, NMAs will be evaluated comprehensively. In treatment effect assessed by indirect and direct comparisons, the potential difference can be evaluated by several methods, and 95% CIs and z-a values will be calculated for each outcome from each study. The antilogy of the model will be explored by using the node-splitting method, which generates a p-value for the difference between direct and indirect estimates in each closed loop in the network (p-values of <0.05 indicate the presence of inconsistency between direct and indirect estimates in a particular closed loop). We will use the deviance information criterion (DIC) to compare the random and fixed effects models to evaluate model fitness by taking references from the guidelines commonly used in the analogous Akaike Information Criteria: values which decrease by at least 10 points indicate significantly better model fit and parsimony. The mean

BMJ Open: first published as 10.1136/bmjopen-2018-023096 on 9 February 2019. Downloaded from http://bmjopen.bmj.com/ on June 10, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

ranks and surface under the cumulative ranking curve (SUCRA) will be used to sequence the probabilities of the optimal intervention of various treatments. We will describe SUCRA with percentages. For the treatment, better ranks are indicated by higher values. Stata v. 12 will be used to generate result figures and NMA graphs. If the data cannot be used for quantitative analysis, the evidence will be described and summarised.

Sensitivity analysis and subgroup analysis

The strategies can be used to address the problem of heterogeneity of pairwise meta-analysis, as well as be employed to tackle incongruity of network analysis. Inconsistent sources will be explored by performing a network meta-regression. We will conduct a sensitivity analysis to explore the strong conclusions of the main results wherever practical. The overall results will be influenced because the methodological quality levels of the studies vary. To conduct sensitivity analysis, we will remove trails that report the generation of non-random sequences.

Publication bias

If feasible, we will also convey any small study effects that exist within a network of interventions. Publication bias will be assessed by performing Egger's regression test. If feasible, a statistical model will be used to convey the network of interventions, including small study effects.

Quality of evidence

For the main outcomes, the quality of evidence will be assessed based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE). Five projects, including the limitations of research design, indirectness, incongruity, imprecision and publication bias, will be investigated.

DISCUSSION

TCE, a series of mind-body exercises including baduanjin, yijinjing, and tai chi (TC, also known as 'taiji chuan') originated in ancient Chinese philosophy. TCE has been practised for over 1,000 years. Based on the theoretical principles of traditional Chinese medicine (TCM), in clinical rehabilitation focuses on posture, meditation,

and coordination of breath. The common characteristics of these movements is that they are slow, relaxing and systematic, and therefore suitable for physically weak patients. By correcting body posture and movements, adjusting breathing patterns, and maintaining stillness of mind, a wide array of natural self-regulatory/self-healing mechanisms can be activated to stimulate the balanced release of endogenous neurohormones²²⁻²³.

Previous reviews have indicated that left ventricular (LV) remodeling after myocardial infarction (MI) can be reduced by baduanjin; Another study demonstrated that baduanjin provides clinically meaningful improvement for SBP, DBP, BMI, blood glucose, TG, HDL-C, LDL-C and QoL²⁴. Research on TC has discovered that it can improve VO₂ max in patients with coronary disease. This suggests that TC could be applied in cardiac rehabilitation (CR) as an adjuvant therapy²⁵; Another study has indicated that TC might improve 6-MWD, QoL, and LVEF in patients, and could be associated with significant reductions in BNP and HR²⁶. This would signify the clinical importance of CR post-PCI. Research has also shown that the effects of TCE on blood pressure and blood lipids commonly acknowledged as the primary targets for cardiovascular risk reduction (e.g. LDL-C) are clinically significant²⁷.

TCE could therefore be used in CR therapy post-PCI, but its efficacy and mechanisms remain unclear. More larger-scale well-designed studies using standardized training protocols are needed in order for specific and accurate conclusions to be made. Thus, the aim of the present study is to systematically assess the effects of TCE on patients in CR post-PCI by using enough studies to ensure adequate power for the meta-analysis. To the best of our knowledge, this review will be the first network meta-analysis to evaluate the impact of TCE for patients in CR post-PCI. We hope the results of this review will help establish a better approach for exploring the potential functions of TCE in CR and will also provide reliable evidence supporting the use of TCE.

Contributors

CL and RL conceived of the study and drafted the protocol. JW, WS and XZ revised it. TL, WW and XY developed the search strategies and conducted data collection. TZ analysed the data independently. All authors have approved the final manuscript.

Funding

This study is supported by the 2017 Diagnosis and Treatment Innovation Project at

The First Affiliated Hospital of Guangzhou University of Chinese Medicine.

Competing interests

None declared.

Provenance and peer review

Not commissioned; externally peer reviewed.

Data sharing statement

No additional data are available.

References:

[1] Claire T, Costas T, James M, William MJ, et al. Submaximal fitness and mortality risk reduction in coronary heart disease: a retrospective cohort study of community-based exercise rehabilitation. Bmj Open. 2016;6(6):e11125.

[2] Eckel RH, Jakicic JM, Ard JD, Jesus JMD, et al. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

[3] Zhang Y, Ma X, Shi D. Effect of Trimetazidine in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis. Plos One. 2015;10(9):e137775.

[4] Dzavik V, Ghali WA, Norris C, Mitchell LB, et al. Long-term survival in 11,661 patients with multivessel coronary artery disease in the era of stenting: a report from the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators. American Heart Journal. 2001;142(1):119-126.

[5] Kastrati A, Pache J, Dirschinger J, Neumann FJ, et al. Primary intracoronary stenting in acute myocardial infarction: long-term clinical and angiographic follow-up and risk factor analysis. American Heart Journal. 2000;139(1):208-216.

[6] Perk J, De BG, Gohlke H, Graham I, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012) : the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by re. European Journal of Preventive Cardiology. 2012;19(4):403-488.

[7] Levine GN, Bates ER, Blankenship JC, Bailey SR, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention : A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for

1	
2	Condisussaular Assistantly, and Interventions, Journal of the American College of Condisions
3	Cardiovascular Anglography and interventions. Journal of the American College of Cardiology.
5	2011;58(24):44-122.
6	[8] Thomas RJ, King M, Lui K, Oldridge N, et al. AACVPR/ACC/AHA 2007 performance measures on
7	cardiac rehabilitation for referral to and delivery of cardiac rehabilitation/secondary prevention
8	services endorsed by the American College of Chest Physicians, American College of Sports Medicine,
9	American Phys. Journal of the American College of Cardiology. 2007;50(14):1400-1433.
10	[9] Anderson JL, Adams CD, Antman EM, Bridges CR, et al. ACC/AHA 2007 Guidelines for the
11	Management of Patients With Unstable Angina/Non – ST-Elevation Myocardial Infarction, Journal of
12	the American College of Cardiology, 2007:50(7):e148.
15	[10] Leon AS, Franklin BA, Costa F, Balady GL et al. Cardiac rehabilitation and secondary prevention
15	of coronary heart diseases: an American Heart Association scientific statement from the Council on
16	of coronary heart disease, an American Heart Association scientific statement from the Council on
17	Clinical Cardiology (Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention) and the
18	Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity), in
19	collaboration with the American association of Cardiovascular and Pulmonary Rehabilitation.
20	Circulation. 2005;111(3):369-376 'doi': 10.1161/01.CIR.0000151788.08740.5C['2005-01-25].
21	[11] Eagle KA, Guyton RA, Davidoff R, Edwards FH, et al. ACC/AHA 2004 guideline update for coronary
22	artery bypass graft surgery: summary article: a report of the American College of
25 74	Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the
25	1999 Guidelines for Coronary Arter. Indian Journal of Thoracic & Cardiovascular Surgery.
26	2004·110/9)·1168
27	[12] Eletcher GE Ades PA Kligfield P Arena R et al Evercise standards for testing and training: a
28	[12] Recent of , Adds FA, Kigheid F, Archa K, et al. Excluse standards for testing and training. a
29	(12) the AC Constitute ID Deserve Detailed in Circulation. 2015;120(8):875.
30	[13] Leon AS, Connett J, Jr JD, Rauramaa R. Leisure-time physical activity levels and risk of coronary
31 20	heart disease and death. The Multiple Risk Factor Intervention Trial. Jama. 1987;258(17):2388-2395.
32	[14] Chan CL, Wang CW, Ho RT, Ho AH, et al. A systematic review of the effectiveness of qigong
34	exercise in cardiac rehabilitation. American Journal of Chinese Medicine. 2012;40(2):255-267.
35	[15] Ding M. Tai Chi for stroke rehabilitation: a focused review. American Journal of Physical
36	Medicine & Rehabilitation. 2012;91(12):1091.
37	[16] Dalusungangosta A. The impact of Tai Chi exercise on coronary heart disease: a systematic
38	review. Journal of the American Academy of Nurse Practitioners. 2011;23(7):376.
39	[17] Yeh GY, Wang C, Wayne PM, Phillips R, Tai chi exercise for patients with cardiovascular
40	conditions and risk factors: A SYSTEMATIC REVIEW Journal of Cardionulmonary Rebabilitation &
41	Prevention 2009/20/3):152
43	[18] L.C. D.M. M.C. D.C. et al. Dreferred reporting items for systematic review and meta analysis
44	[16] L S, D W, W C, D G, et al. Preferred reporting items for systematic review and meta-analysis
45	protocols (PRISMA-P) 2015: elaboration & explanation. Systematic Reviews. 2015;4(1):1.
46	[19] Savovic J, Page M, Elbers R, Hrobjartsson A, et al. A revised tool for assessing risk of bias in
47	randomized trials (RoB 2.0). TRIALS. 2017;181.
48	[20] Fellow JPHS. Chapter 8. Assessing Risk of Bias in Included Studies.: John Wiley & Sons, Ltd, 2008.
49 50	[21] Salanti G, Del GC, Chaimani A, Caldwell DM, Higgins JP. Evaluating the quality of evidence from a
50	network meta-analysis. Plos One. 2014;17(7):A324.
52	[22] Wang XQ, Pi YL, Chen PJ, Yu L, et al. Traditional Chinese Exercise for Cardiovascular Diseases:
53	Systematic Review and Meta - Analysis of Randomized Controlled Trials. Journal of the American
54	Heart Association Cardiovascular & Cerebrovascular Disease. 2016:5(3):e2562.
55	
56	
5/	
58 59	11
60	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2018-023096 on 9 February 2019. Downloaded from http://bmjopen.bmj.com/ on June 10, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES)

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

[23] Jahnke R, Larkey L, Rogers C, Etnier J, Lin F. A Comprehensive Review of Health Benefits of Qigong and Tai Chi. American Journal of Health Promotion Ajhp. 2010;24(6):e1.

[24] Mao S, Zhang X, Shao B, Hu X, et al. Baduanjin Exercise Prevents post-Myocardial Infarction Left Ventricular Remodeling (BE-PREMIER trial): Design and Rationale of a Pragmatic Randomized Controlled Trial. Cardiovascular Drugs & Therapy. 2016;30(3):315.

[25] Xiong X, Wang P, Li S, Zhang Y, Li X. Effect of Baduanjin exercise for hypertension: A systematic review and meta-analysis of randomized controlled trials. Maturitas. 2015;80(4):370-378.

[26] Yang YL, Wang YH, Wang SR, Shi PS, Wang C. The Effect of Tai Chi on Cardiorespiratory Fitness for Coronary Disease Rehabilitation: A Systematic Review and Meta-Analysis. Frontiers in Physiology. 2017;8:1091.

[27] Ren X, Li Y, Yang X, Li J, et al. The Effects of Tai Chi Training in Patients with Heart Failure: A Systematic Review and Meta-Analysis. Frontiers in Physiology. 2017;8:989.



	Table 1. Search strategy utilized for the Publied database
No.	Search terms
1	Tai Ji Quan
2	Tai chi
3	Tai ji
4	Taijiquan
5	Baduanjin
6	Baduanjin exercise
7	eight section brocades
8	Yi Jinjing
9	Yijinjing
10	Yijinjing exercise
11	or1-10
12	Coronary Heart Diseases
13	CHD
14	Coronary artery atherosclerosis heart disease
15	Acute coronary syndrome
16	ACS
17	Acute myocardial infarction
18	AMI
19	Heart failure
20	HF
21	Cardiovascular events
22	percutaneous coronary intervention
23	PCI
24	or12-23
25	11 and 24

BMJ Open

Figure 1. Traditional Chinese exercise (A is Tai chi, B is Baduanjin, C is Yi Jinjing). Figure 2. Network plot of all possible direct comparisons between the eligible interventions. Figure 3. Flow diagram of the study selection process.

to beet to the month









PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

Section and topic	Item No	Checklist item	Reported on page #		
ADMINISTRATIVE	ADMINISTRATIVE INFORMATION				
Title:					
Identification	1a	Identify the report as a protocol of a systematic review	1		
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	no		
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	3		
Authors:					
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1		
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	14		
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	no		
Support:					
Sources	5a	Indicate sources of financial or other support for the review	14		
Sponsor	5b	Provide name for the review funder and/or sponsor	14		
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	14		
INTRODUCTION					
Rationale	6	Describe the rationale for the review in the context of what is already known	4-6		
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	2-3		
METHODS					
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	6-7		
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	6		
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	7-8		

Data management 11a Describe the mechanism(s) that will be used to manage records and data throughout the review 7 Selection process 11b State the process that will be used for selecting studies (such as two independent reviewers) through each phase 8 of the review (that is, screening, eligibility and inclusion in meta-analysis) 8.9 Data collection process 11e Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators 8.9 Data items 12 List and define all variables for which data will be sought (such as PICO items, funding sources), any pre- planned data assumptions and simplifications 8-10 Outcomes and prioritization 13 List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale 7 Risk of bias in individual studies 14 Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis 10,11 Data synthesis 15a Describe criteria under which study data will be quantitatively synthesised 10,11 15b If data are appropriate for quantitative synthesis, describe planned ascenser, methods of handling data and methods of combining data from studies, including any planned 11,12	Study records.			
Selection process 11b State the process that will be used for selecting studies (such as two independent reviewers) through each phase 8 of the review (that is, screening, eligibility and inclusion in meta-analysis) Data collection process 11c Describe planned method of extracting data from reports (such as piloting forms, done independently, in 8,9 duplicate), any processes for obtaining and confirming data from investigators 8,9 Data items 12 List and define all variables for which data will be sought, such as PICO items, funding sources), any preplanned data assumptions and simplifications Outcomes and prioritization 13 List and define all variables for which data will be sought, including prioritization of main and additional outcomes, with rationale 7 Outcomes, with rationale 0 0 11,12 0 dividual studies 0 Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be used in data synthesis 10,11 15a Describe criteria under which study data will be quantitatively synthesised 10,11 15b If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I ² , Kendall's r) 12 15c Describe any proposed additional analyses (such as sensitivity or subgroup analyses, me	Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	7
Data collection process 11c Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators 8,9 Data items 12 List and define all variables for which data will be sought (such as PICO items, funding sources), any pre- planned data assumptions and simplifications 8-10 Outcomes and prioritization 13 List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale 7 Outa synthesis 14 Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis 10,11 Data synthesis 15a Describe anticipated rethods of combining data from studies, including any planned exploration of consistency (such as 1 ² , Kendall's τ) 10-12 data and methods of combining data from studies, including any planned exploration of consistency (such as 1 ² , Kendall's τ) 15c Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression) 11,12 Meta-bias(es) 16 Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies) 12 Confidence in cumulative evidence 17 De	Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	e 8
Data items 12 List and define all variables for which data will be sought (such as PICO items, funding sources), any preplanned data assumptions and simplifications 8-10 Outcomes and prioritization 13 List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale 7 Risk of bias in individual studies 14 Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both, state how this information will be used in data synthesis 10,11 Data synthesis 15a Describe criteria under which study data will be quantitatively synthesised 10,11 15b If data are appropriate for quantitative synthesis, including any planned exploration of consistency (such as I ² , Kendall's r) 10-12 15c Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression) 11,12 Meta-bias(es) 16 Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies) 12 * It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0. <	Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	8,9
Outcomes and prioritization 13 List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale 7 Risk of bias in individual studies 14 Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis 11,12 Data synthesis 15a Describe criteria under which study data will be quantitatively synthesised 10,11 15b If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I ² , Kendall's τ) 10-12 15c Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression) 11,12 Meta-bias(es) 16 Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies) 12 Confidence in cumulative evidence 17 Describe how the strength of the body of evidence will be assessed (such as GRADE) 12 * It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed un	Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre- planned data assumptions and simplifications	8-10
Risk of bias in 14 Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis 11,12 Data synthesis 15a Describe criteria under which study data will be quantitatively synthesised 10,11 15b If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I ² , Kendall's τ) 10-12 15c Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression) 11,12 15b If quantitative synthesis is not appropriate, describe the type of summary planned 11,12 15c Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression) 11,12 15c Describe any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting 12 Meta-bias(es) 16 Specify any planned assessment of meta-bias(es) (such as GRADE) 12 Confidence in cumulative evidence 17 Describe how the strength of the body of evidence will be assessed (such as GRADE) 12 * It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important	Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	7
Data synthesis 15a Describe criteria under which study data will be quantitatively synthesised 10,11 15b If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling 10-12 15b If data are appropriate for quantitative synthesis, describe planned summary measures, methods of consistency (such as 1 ² , Kendall's τ) 10-12 15c Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression) 11,12 15d If quantitative synthesis is not appropriate, describe the type of summary planned 11,12 Meta-bias(es) 16 Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting uvithin studies) 12 Confidence in cumulative evidence 17 Describe how the strength of the body of evidence will be assessed (such as GRADE) 12 * It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0. From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group, Preferred reporting items for systematic review of the systematic review of the systematic review of the systematic review of the systematic revi	Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	11,12
15b If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I ² , Kendall's τ) 10-12 15c Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression) 11,12 15d If quantitative synthesis is not appropriate, describe the type of summary planned 11,12 Meta-bias(es) 16 Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting uithin studies) 12 Confidence in cumulative evidence 17 Describe how the strength of the body of evidence will be assessed (such as GRADE) 12 * It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0. From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review of the system	Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	10,11
15c Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression) 11,12 15d If quantitative synthesis is not appropriate, describe the type of summary planned 11,12 Meta-bias(es) 16 Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting uithin studies) 12 Confidence in cumulative evidence 17 Describe how the strength of the body of evidence will be assessed (such as GRADE) 12 * It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0. From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review of the systematic rev		15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I^2 , Kendall's τ)	, 10-12
15d If quantitative synthesis is not appropriate, describe the type of summary planned 11,12 Meta-bias(es) 16 Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting 12 Confidence in cumulative evidence 17 Describe how the strength of the body of evidence will be assessed (such as GRADE) 12 * It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0. From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Peticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review of the systema		15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	11,12
Meta-bias(es) 16 Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting in the within studies) 12 Confidence in cumulative evidence 17 Describe how the strength of the body of evidence will be assessed (such as GRADE) 12 * It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0. From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review of the systematic revi		15d	If quantitative synthesis is not appropriate, describe the type of summary planned	11,12
Confidence in cumulative evidence 17 Describe how the strength of the body of evidence will be assessed (such as GRADE) 12 * It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0. From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review of the systematic review of t	Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	12
* It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.	Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	12
meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2:349(jan02 1):g7647.	* It is strongly recomn clarification on the ite PRISMA-P Group and	nended ms. An d is dis <i>her</i> D	that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when av nendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including che tributed under a Creative Commons Attribution Licence 4.0. Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting item	vailable) for important ecklist) is held by the as for systematic review an

×

The Effects of Traditional Chinese Exercise on Cardiac Rehabilitation After Percutaneous Coronary Intervention : Study Protocol for Network Meta-analysis of Randomized Controlled Trials

Journal:	BMJ Open
Manuscript ID	bmjopen-2018-023096.R1
Article Type:	Protocol
Date Submitted by the Author:	22-Oct-2018
Complete List of Authors:	Luo, Chuanjin; First Affiliated Hospital of Guangzhou University of Chinese Medicine, Department of Cardiovascular Disease Wen, Junmao; Guangzhou University of Chinese Medicine Sun, Weipeng; Guangzhou University of Chinese Medicine Li, Ting; Guangzhou University of Chinese Medicine Yu, Xiaojiang; First Affiliated Hospital of Guangzhou University of Chinese Medicine, Department of Rehabilitation Center Zhang, Tian; Guangzhou University of Chinese Medicine Zhou, Xiaoqi; Guangzhou University of Chinese Medicine Wu, Wei; First Affiliated Hospital of Guangzhou University of Chinese Medicine, Department of Cardiovascular Disease Li, Rong;
Primary Subject Heading :	Complementary medicine
Secondary Subject Heading:	Complementary medicine
Keywords:	Traditional Chinese Exercise, Cardiac Rehabilitation, Coronary heart disease < CARDIOLOGY

SCHOLARONE[™] Manuscripts

1 2 3 4 5 6 7	The Effects of Traditional Chinese Exercise on Cardiac Rehabilitation After Percutaneous Coronary Intervention: Study Protocol for Network Meta-analysis of Randomized Controlled Trials
9 10	Authors
11	Chuanjin Luo ¹ , Junmao Wen ² , Weipeng Sun ² , Ting Li ² , Xiaojiang Yu ³ , Tian Zhang ² ,
12	Xiaoqi Zhou ¹ , Wei Wu ¹ , Rong Li ^{1*}
14 15	¹ Department of Cardiovascular Disease First Affiliated Hospital of Guangzhou
16 17	University of Chinese Medicine Guangzhou, China
18 19	² Guangzhou University of Chinese Medicine, Guangzhou, China
20 21	3D to the CD 1 1 11/1 (Control End of Control End o
22	Department of Renabilitation Center, First Affiliated Hospital of Guangzhou University
23 24	of Chinese Medicine, Guangzhou, China
25	Corresponding author
26 27	Professor Rong Li
28	Email: 256298797@gg.com
29 30	Tel: 020-36591357
31	
32 33	Present address
34	Guangzhou University of Chinese Medicine, No. 12, Ji Chang Road, Baiyun District,
36	Guangzhou 510405. China
37	
39	
40	
41 42	
43	
44	
45 46	
40	
48	
49	
50	
51	
53	
54	
55	
56	
57 58	1
50	1

60

BMJ Open: first published as 10.1136/bmjopen-2018-023096 on 9 February 2019. Downloaded from http://bmjopen.bmj.com/ on June 10, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) .

tand

data mining, Al training, and similar technologies

Protected by copyright, including for uses related to text

ABSTRACT

Introduction: Coronary heart disease (CHD) is the most common cause of death worldwide. Percutaneous coronary intervention (PCI) has been shown to reduce mortality in patients with CHD. However, there are still recurrences of cardiovascular events after PCI. Cardiac rehabilitation (CR) in patients with established CHD is associated with reductions in cardiovascular mortality and hospital admissions, as well as improved quality of life. More and more clinical trials suggest that traditional Chinese exercise (TCE) plays a positive role in patients post-PCI.

Objective: The primary purposes of the current study are to conduct a network meta-analysis of randomized trials to determine the effects of TCE in patients after PCI, and to separately compare the effects of tai chi, baduanjin and yijinjing on cardiac rehabilitation after PCI.

Methods and analysis: Studies will be retrieved from the following databases: PubMed, Embase, Cochrane Library, Chinese National Knowledge Infrastructure, Wanfang Data, Chinese BioMedical Database and Chinese Science and Technology Periodicals Database, from inception to February 2018. We will include RCTs that are related to the effects of TCE therapies in patients after PCI. The primary outcomes will be all-cause mortality, revascularisations, health-related quality of life (HRQL), and hospitalisations. Two reviewers will independently select eligible articles. For each included article, two reviewers will independently extract the data and assess the risk of bias by using the Cochrane risk of bias tool. Bayesian network meta-analyses will be conducted to pool all treatment effects. The ranking probabilities for the optimal intervention of various treatments (tai chi, baduanjin or yijinjing) will be estimated by the mean ranks and surface under the cumulative ranking curve (SUCRA). The Grading of Recommendations

Assessment, Development and Evaluation System will be utilized to assess the quality of evidence.

Ethics and dissemination: The results will be disseminated through peer-reviewed publications. They will provide consolidated evidence to inform clinicians on the potential functions of TCE in CR, and to provide reliable evidence for the application of TCE.

Trial registration number: CRD42018088415

Strengths and limitations of this study

- This is the first systematic review to use network meta-analysis to compare various forms of traditional Chinese exercise.
- This is the first systematic review to compare the effects of baduanjin, yijinjing and tai chi on cardiac rehabilitation post-PCI.
- This study will assess the effects of TCEs and their safety regarding cardiac rehabilitation after PCI.
- The study will use the Grading of Recommendations Assessment, Development and Evaluation System to further assess the quality of the evidence.
- Due to the changes in the frequency and duration of treatment, there may be methodological heterogeneity.

INTRODUCTION

Description of the condition

Coronary heart disease (CHD), also known as coronary artery disease (CAD), is the most common cause of death worldwide, causing 7.4 million deaths in 2013, accounting for one-third of all deaths globally (WHO 2014)¹. In addition to the requisite medical therapy, mechanical revascularization with coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) is needed for patients with CHD. PCI has been shown to reduce mortality in patients with CHD². During follow-up, however, the benefits of PCI surgery still carry significant risks of coronary spasm, endothelial cell

injury, recurrent ischemia, and even restenosis or thrombus³⁻⁵. Numerous guidelines endorse the benefits of cardiac rehabilitation (CR), which is recommended for patients with chronic stable angina, acute coronary syndromes or for patients post-PCI surgery^{2,6-10}. Combined with routine therapy, exercise-based CR, which has been recommended by American Heart Association (AHA) guidelines¹¹, is a safe option. It has been reported that light to moderate intensity physical activity can reduce coronary heart disease mortality¹².

Description of the intervention

For centuries, traditional Chinese exercise (TCE) (Figure 1), a series of mind-body exercises including baduanjin, vijinjing, and tai chi (TC, also known as 'taiji chuan'), has been widely practiced in China for both preventive and therapeutic purposes. Based on the theoretical principles of traditional Chinese medicine (TCM), in clinical rehabilitation focuses on posture, meditation, and coordination of breath. The common characteristics of these movements is that they are slow, relaxing and systematic, and therefore suitable for physically weak patients. By correcting body posture and movements, adjusting breathing patterns, and maintaining stillness of mind, a wide array of natural self-regulatory/self-healing mechanisms can be activated to stimulate the balanced release of endogenous neurohormones¹³⁻¹⁴. Considered to be a low-risk, promising intervention that is used widely in the prevention of cardiovascular disease, TCEs are easy to master in a short time and have few physical demands¹⁵. Regardless of previous exercise experience or aerobic capacity, the exercise intensity of TCE is suited for persons of all ages. Moreover, TCE requires no expensive equipment and can be performed either individually or in groups. Most existing systematic reviews have focused on specific forms of TCE, such as tai chi or baduanjin¹⁶⁻¹⁸. Whether TCE has positive clinical effects on patients with CHD after PCI, however, remains unclear.

Therefore, we will conduct the present network meta-analysis to explore whether TCE affects the primary endpoint events of cardiac death, recurrence of MI, repeated PCI, and restenosis after PCI; to determine whether TCE could be an effective method for

BMJ Open

improving secondary endpoint measures such as quality of life (QoL), physical functions and symptoms, after PCI; to separately compare the effects of Tai chi, Baduanjin and Yijinjing on patients post-PCI. (Figure 2)

METHODS AND ANALYSIS

Registration

This protocol has been developed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement. It has also been registered with the International Prospective Register of Systematic Reviews (registration number CRD42018088415).¹⁹

Supplementary Appendix (Patient_Consent)

The pictured individual had signed a consent form confirming that he understood the situation (Appendix of "Patient_Consent").

Eligibility criteria

Study type

We will include randomised controlled trials that compare the effects of three different traditional Chinese exercise therapies (Tai chi, Baduanjin and Yijinjing) with a no exercise control on patients with CHD following PCI. The following study designs or publication types will be excluded: (1) non-clinical research literature, such as animal experiments, reviews or case reports; (2) duplicate publications; (3) literature with incomplete data, the study of chaos; (4) studies which lack primary outcome measures. If multiple intervention data can be obtained, the trails can be adopted. If data for comparison of multiple interventions cannot be directly obtained, we will try E-mailing the corresponding author to obtain the original data. If the data cannot be obtained, the trails will also be excluded.

Participants

This network-analysis will include patients with coronary heart disease who have received TCE intervention after PCI.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Patient and Public Involvement

patients and public will not be involved.

Interventions

We plan to include the following TCE therapies: tai chi, baduanjin and yijinjing, and patients who have received TCE interventions either alone or in combination with appropriate training. For comparisons, both active (e.g. walking) or non-active (e.g. usual care) controls compared with TCEs will be included. For the reason that some RCTs set a placebo controlled arm as the comparator, information about interventions from placebo controlled trails will also be extracted.

Outcomes

The primary outcomes will include: (1) all-cause mortality; (2) revascularisations (CABG or PTCA); (3)results of Medical Outcome Study (MOS) 36-Item Short-Form Health Survey (SF-36); (4) hospitalisations: hospital readmission dates.

The secondary outcomes will include: (1) b-type natriuretic peptide ; (2) blood lipid indexes (i.e. serum total cholesterol, triglyceride , low density lipoprotein cholesterol and high-density lipoprotein cholesterol); (3) echocardiography; (4) adverse events. *Search strategy*

BMJ Open

Sun and Ting Li) who will independently review the full texts of potentially eligible studies. Discrepancies regarding included studies will be discussed and settled by a third reviewer.

Data collection process

All titles and abstracts of potential trials will be retrieved and organised by two authors (Weipeng Sun and Ting Li) in Endnote X7. Duplicate records will be excluded. The database will then be copied and provided to the first author for duplicate screening. Any disagreements between the two authors will be resolved by discussion with the whole team at a regular meeting. We will allocate the trials to the following five groups: inclusion group, non-patient group, intervention group, outcome group and awaiting group. For this project, Microsoft Excel will be used for preliminary data collection. Four spreadsheets including general information (i.e. author list, publication year, and journal, etc), characteristics of the included trials (i.e. diagnostic criteria, age range, study drugs, and dose range, etc), risk of bias assessed using the Cochrane risk of bias assessment tool¹⁹ and outcome data extraction (i.e. numbers of response events and non-response events, time points, mean or mean difference, reported outcome definitions, summary data related to treatment effects, etc.), will be represented in the table. Relevant original data will be submitted as attachments.

We will express the study selection and data colletion process with a PRISMA flow chart (http://www.prisma-statement.org) (Figure 3).

Quality assessment

The methodological quality of the eligible studies, concealment allocation, covering randomisation, blinding and other biases will be evaluated by two authors (Tian Zhang, Xiaoqi Zhou) according to the Cochrane risk of bias assessment tool ²⁰. Particular attention will be paid to the adequacy of random allocation concealment and blinding due to the potential failure of inadequate concealment in the randomisation test. Considering the diagnostic criteria, the sample size calculation method, reporting of withdrawals and

follow-up, any other sources of bias will be cautiously assessed. The complete assessment procedures are as follows²¹: (1) offer direct and indirect effect estimates; (2) assess the quality of direct and indirect estimates; (3) present the results of the network meta-analysis; (4) assess the quality of the network meta-analysis effect estimates.

Dealing with missing data

We will initially contact both senior and/or corresponding author to obtain any missing data. If no one responds, the following approaches will be used to estimate the missing data. Instead of providing the mean and SD, the number of responding patients employing a validated imputation method will be calculated for studies failing to report the patients' numbers after treatment. We will also try to estimate from graphs if possible. The reason for exclusion of the available data will be reported.

Network meta-analysis

We will use the Markov Chain Monte Carlo algorithm (MCMC) by applying WinBUGS 1.4.3 to conduct the network meta-analysis (NMA) in a Bayesian hierarchical framework. The inverse variance heterogeneity method will be used in order to overcome the limitations of the fixed and random effects models. Minimally informative prior distributions will be used for the main outcome. The magnitude of heterogeneity variance will be used to investigate the statistical heterogeneity of all of the NMAs.If direct evidence is feasible, NMAs will be evaluated comprehensively. In treatment effect assessed by indirect and direct comparisons, the potential difference can be evaluated by several methods, and 95% CIs and z-a values will be calculated for each outcome from each study. The antilogy of the model will be explored by using the node-splitting method, which generates a p-value for the difference between direct and indirect estimates in each closed loop in the network (p-values of < 0.05 indicate the presence of inconsistency between direct and indirect estimates in a particular closed loop). We will use the deviance information criterion (DIC) to compare the random and fixed effects models to evaluate model fitness by taking references from the guidelines commonly used in the analogous Akaike Information Criteria: values which decrease by at least 10

points indicate significantly better model fit and parsimony. The mean ranks and surface under the cumulative ranking curve (SUCRA) will be used to sequence the probabilities of the optimal intervention of various treatments. We will describe SUCRA with percentages. For the treatment, better ranks are indicated by higher values. Stata 12 will be used to generate result figures and NMA graphs. If the data cannot be used for quantitative analysis, the evidence will be described and summarised.

Sensitivity analysis and subgroup analysis

The strategies can be used to address the problem of heterogeneity of pairwise meta-analysis, as well as be employed to tackle incongruity of network analysis. Inconsistent sources will be explored by performing a network meta-regression. We will conduct a sensitivity analysis to explore the strong conclusions of the main results wherever practical. The overall results will be influenced because the methodological quality levels of the studies vary. Sensitivity analysis will be conducted to exclude trials with small sample sizes (i.e. arms of less than 10 patients) and remove trails that report the generation of non-random sequences. It is planned (if the number of trials is high enough) to perform sensitivity analysis with respect to age difference and geographical region.

BMJ Open: first published as 10.1136/bmjopen-2018-023096 on 9 February 2019. Downloaded from http://bmjopen.bmj.com/ on June 10, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Publication bias

If feasible, we will also convey any small study effects that exist within a network of interventions. Publication bias will be assessed by performing Egger's regression test. If feasible, a statistical model will be used to convey the network of interventions, including small study effects.

Quality of evidence

For the main outcomes, two authors (Xiaojiang Yu, Wei Wu) will assess the quality of evidence based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE), covering study limitations, inconsistency, indirectness,

imprecision and publication bias. Five factors, including the limitations of research design, indirectness, incongruity, imprecision and publication bias, will be investigated.

DISCUSSION

Previous reviews have indicated that left ventricular (LV) remodeling after myocardial infarction (MI) can be reduced by baduanjin; Another study demonstrated that baduanjin provides clinically meaningful improvement for SBP, DBP, BMI, blood glucose, TG, HDL-C, LDL-C and QoL²². Research on TC has discovered that it can improve VO₂ max in patients with coronary disease. This suggests that TC could be applied in cardiac rehabilitation (CR) as an adjuvant therapy²³; Another study has indicated that TC might improve 6-MWD, QoL, and LVEF in patients, and could be associated with significant reductions in BNP and HR²⁴. This would signify the clinical importance of CR post-PCI. Research has also shown that the effects of TCE on blood pressure and blood lipids commonly acknowledged as the primary targets for cardiovascular risk reduction (e.g. LDL-C) are clinically significant²⁵.

TCE could therefore be used in CR therapy post-PCI, but its efficacy and mechanisms remain unclear. More larger-scale well-designed studies using standardized training protocols are needed in order for specific and accurate conclusions to be made. Thus, the aim of the present study is to systematically assess the effects of TCE on patients in CR post-PCI by using enough studies to ensure adequate power for the meta-analysis. To the best of our knowledge, this review will be the first network meta-analysis to evaluate the impact of TCE for patients in CR post-PCI. We hope the results of this review will help establish a better approach for exploring the potential functions of TCE in CR and will also provide reliable evidence supporting the use of TCE.

1	
2	
2	
1	
4 5	
5	
6	
7	
8	
9	
10	
11	
11	
12	
13	
14	
15	
16	
17	
10	
10	
19	
20	
21	
22	
23	
24	
25	
25	
20	
27	
28	
29	
30	
31	
32	
22	
22	
34	
35	
36	
37	
38	
30	
10	
40	
41	
42	
43	
44	
45	
46	
.0 47	
-T/ /0	
48	
49	
50	
51	
52	
53	
51	
54	
55	
56	
57	
58	
59	
60	

Contributors

CL and RL conceived of the study and drafted the protocol. JW, WS and XZ revised it.

TL, WW and XY developed the search strategies and conducted data collection. TZ

analysed the data independently. All authors have approved the final manuscript.

Funding

This study is supported by the 2017 Diagnosis and Treatment Innovation Project at The First Affiliated Hospital of Guangzhou University of Chinese Medicine.

Competing interests

None declared.

Provenance and peer review

Not commissioned; externally peer reviewed.

Data sharing statement

No additional data are available.

Consent for the pictured individual

The pictured individual had signed a consent form confirming that he understood the situation (Appendix of "Patient Consent").

Reference:

[1] Claire T, Costas T, James M, et al. Submaximal fitness and mortality risk reduction in coronary heart disease: a retrospective cohort study of community-based exercise rehabilitation:[J]. Bmj Open, 2016, 6(6):e011125.

[2] Levine G N, Bates E R, Blankenship J C, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology
Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.[J]. Circulation, 2011, 124(23):2574-609.

[3] Zhang Y, Ma X J, Shi D Z. Effect of Trimetazidine in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis[J]. Plos One, 2015, 10(9):e0137775.

[4] Dzavik V, Ghali WA, Norris C, Mitchell LB, et al. Long-term survival in 11,661
patients with multivessel coronary artery disease in the era of stenting: a report from the
Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease
(APPROACH) Investigators. American HeartJournal. 2001;142(1):119-126
[5] Kastrati A, Pache J, Dirschinger J, Neumann FJ, et al. Primary intracoronary stenting
in acute myocardial infarction: long-term clinical and angiographic follow-up and risk

factor analysis. AmericanHeart Journal. 2000;139(1):208-216.

[6] Perk J, De BG, Gohlke H, Graham I, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012) : the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted byre. European Journal of Preventive Cardiology. 2012;19(4):403-488.

[7] Thomas RJ, King M, Lui K, Oldridge N, et al. AACVPR/ACC/AHA 2007 performance measures oncardiac rehabilitation for referral to and delivery of cardiac rehabilitation/secondary preventionservices endorsed by the American College of Chest Physicians, American College of Sports Medicine, American Phys. Journal of the American College of Cardiology. 2007;50(14):1400-1433.

[8] Anderson JL, Adams CD, Antman EM, Bridges CR, et al. ACC/AHA 2007
Guidelines for the Management of Patients With Unstable Angina/Non - ST-Elevation
Myocardial Infarction. Journal of the American College of Cardiology. 2007;50(7):e148.
[9] Leon Arthur S,Franklin Barry A,Costa Fernando et al. Cardiac rehabilitation and
secondary prevention of coronary heart disease: an American Heart Association scientific
statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Cardiac
Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and
Metabolism (Subcommittee on Physical Activity), in collaboration with the American
association of Cardiovascular and Pulmonary Rehabilitation.[J] .Circulation, 2005,

111(3): 369-76.

[10] Eagle Kim A, Guyton Robert A, Davidoff Ravin et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery).[J] .J. Am. Coll. Cardiol., 2004, 44(5): e213-310. BMJ Open: first published as 10.1136/bmjopen-2018-023096 on 9 February 2019. Downloaded from http://bmjopen.bmj.com/ on June 10, 2025 at Agence Bibliographique de Enseignement Superieur (ABES)

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

[11] Fletcher GF, Ades PA, Kligfield P, Arena R, et al. Exercise standards for testing and training: a scientific statement from the American Heart Association. Circulation. 2013;128(8):873.

[12] Leon AS, Connett J, Jr JD, Rauramaa R. Leisure-time physical activity levels and risk of coronary heart disease and death. The Multiple Risk Factor Intervention Trial. Jama. 1987;258(17):2388-2395.

[13] Wang XQ, Pi YL, Chen PJ, Yu L, et al. Traditional Chinese Exercise for Cardiovascular Diseases:Systematic Review and Meta - Analysis of Randomized Controlled Trials. Journal of the American Heart Association Cardiovascular & Cerebrovascular Disease. 2016;5(3):e2562.

[14] Jahnke Roger, Larkey Linda, Rogers Carol et al. A comprehensive review of health benefits of qigong and tai chi.[J] .Am J Health Promot, 2010, 24(6): e1-e25.

[15] Chan CL, Wang CW, Ho RT, Ho AH, et al. A systematic review of the effectiveness of qigong exercise in cardiac rehabilitation. American Journal of Chinese Medicine.2012;40(2):255-267.

[16] Ding M. Tai Chi for stroke rehabilitation: a focused review. American Journal of Physical Medicine & Rehabilitation. 2012;91(12):1091.

[17] Dalusungangosta A. The impact of Tai Chi exercise on coronary heart disease: a systematic review. Journal of the American Academy of Nurse Practitioners.2011;23(7):376.

[18] Yeh GY, Wang C, Wayne PM, Phillips R. Tai chi exercise for patients with cardiovascular conditions and risk factors: A SYSTEMATIC REVIEW. Journal of Cardiopulmonary Rehabilitation & Prevention. 2009;29(3):152.

[19] Shamseer Larissa, Moher David, Clarke Mike et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation.[J] .BMJ, 2015, 350: g7647.

[20] Savovic J, Page M, Elbers R, Hrobjartsson A, et al. A revised tool for assessing risk of bias in randomized trials (RoB 2.0). TRIALS. 2017;181.

[21] Salanti G, Del GC, Chaimani A, Caldwell DM, Higgins JP. Evaluating the quality of evidence from anetwork meta-analysis. Plos One. 2014;17(7):A324.

[22] Mao S, Zhang X, Shao B, Hu X, et al. Baduanjin Exercise Prevents post-Myocardial Infarction LeftVentricular Remodeling (BE-PREMIER trial): Design and Rationale of a Pragmatic Randomized Controlled Trial. Cardiovascular Drugs & Therapy. 2016;30(3):315.

[23] Xiong X, Wang P, Li S, Zhang Y, Li X. Effect of Baduanjin exercise for hypertension: A systematic review and meta-analysis of randomized controlled trials. Maturitas. 2015;80(4):370-378.

BMJ Open

[24] Yang YL, Wang YH, Wang SR, Shi PS, Wang C. The Effect of Tai Chi on Cardiorespiratory Fitness for Coronary Disease Rehabilitation: A Systematic Review and Meta-Analysis. Frontiers in Physiology.2017;8:1091. [25] Ren X, Li Y, Yang X, Li J, et al. The Effects of Tai Chi Training in Patients with Heart Failure: A Systematic Review and Meta-Analysis. Frontiers in Physiology. 2017;8:989 to beet eview only

Table 1. Search strategy utilized for the PubMed database Soorah tarma

No.	Search terms
1	Tai Ji Quan
2	Tai chi
3	Tai ji
4	Taijiquan
5	Baduanjin
6	Baduanjin exercise
7	eight section brocades

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2018-023096 on 9 February 2019. Downloaded from http://bmjopen.bmj.com/ on June 10, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

2	
3	
Δ	
-	
ر م	
6	
/	
8	
9	
10	
11	
12	
13	
14	
15	
10	
10	
17	
18	
19	
20	
21	
22	
23	
24	
27	
25	
26	
27	
28	
29	
30	
31	
32	
33	
31	
24	
35	
36	
37	
38	
39	
40	
41	
42	
43	
11	
44	
45	
46	
47	
48	
49	
50	
51	
52	
52	
22	
54	
55	
56	
57	
58	
59	

60

1

8	Yi Jinjing
9	Yijinjing
10	Yijinjing exercise
11	or1-10
12	Coronary Heart Diseases
13	CHD
14	Coronary artery atherosclerosis heart disease
15	Acute coronary syndrome
16	ACS
17	Acute myocardial infarction
18	AMI
19	Heart failure
20	HF
21	Cardiovascular events
22	percutaneous coronary intervention
23	PCI
24	or12-23
25	11 and 24

Figure 1. Traditional Chinese exercise (A is Tai chi, B is Baduanjin, C is Yi Jinjing). Figure 2. Network plot of all possible direct comparisons between the eligible interventions.

Figure 3. Flow diagram of the study selection process.

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.	Open: first published as 10.1136/bmjopen-2018-023096 on 9 February 2019. Downloaded from http://bmjopen.bmj.com/ on June 10, 2025 at Agence Bibliograp
--	--

1	7

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

tor per terien only



175x175mm (300 x 300 DPI)

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml



BMJ Open: first published as 10.1136/bmjopen-2018-023096 on 9 February 2019. Downloaded from http://bmjopen.bmj.com/ on June 10, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.





Identification

Screening

Eligibility

Included

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

Section and topic	Item No	Checklist item	Reported on page #
ADMINISTRATIVE	INFOR	RMATION	
Title:			
Identification	1a	Identify the report as a protocol of a systematic review	1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	no
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	3
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	14
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	no
Support:			
Sources	5a	Indicate sources of financial or other support for the review	14
Sponsor	5b	Provide name for the review funder and/or sponsor	14
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	14
INTRODUCTION			
Rationale	6	Describe the rationale for the review in the context of what is already known	4-6
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	2-3
METHODS			
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	6-7
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	6
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	7-8

Study records.			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	7
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	8
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	8,9
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre- planned data assumptions and simplifications	8-10
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	7
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	11,12
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	10,11
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I^2 , Kendall's τ)	10-12
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	11,12
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	11,12
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	12
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	12
* It is strongly recomn	nended ms. An	that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when avaiendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist tributed up den a Constitue Commons Attribution Lisense 4.0	allable) for important cklist) is held by the

×

The Effects of Traditional Chinese Exercise on Cardiac Rehabilitation After Percutaneous Coronary Intervention : Study Protocol for Network Meta-analysis of Randomized Controlled Trials

Journal:	BMJ Open
Manuscript ID	bmjopen-2018-023096.R2
Article Type:	Protocol
Date Submitted by the Author:	27-Nov-2018
Complete List of Authors:	Luo, Chuanjin; First Affiliated Hospital of Guangzhou University of Chinese Medicine, Department of Cardiovascular Disease Wen, Junmao; Guangzhou University of Chinese Medicine Sun, Weipeng; Guangzhou University of Chinese Medicine Li, Ting; Guangzhou University of Chinese Medicine Yu, Xiaojiang; First Affiliated Hospital of Guangzhou University of Chinese Medicine, Department of Rehabilitation Center Zhang, Tian; Guangzhou University of Chinese Medicine Zhou, Xiaoqi; Guangzhou University of Chinese Medicine Wu, Wei; First Affiliated Hospital of Guangzhou University of Chinese Medicine, Department of Cardiovascular Disease Li, Rong;
Primary Subject Heading :	Complementary medicine
Secondary Subject Heading:	Complementary medicine
Keywords:	Traditional Chinese Exercise, Cardiac Rehabilitation, Coronary heart disease < CARDIOLOGY

SCHOLARONE[™] Manuscripts

Authors

Chuanjin Luo¹, Junmao Wen², Weipeng Sun², Ting Li², Xiaojiang Yu³, Tian Zhang²,

Xiaoqi Zhou¹, Wei Wu¹, Rong Li^{1*}

¹Department of Cardiovascular Disease, First Affiliated Hospital of Guangzhou

University of Chinese Medicine, Guangzhou, China

²Guangzhou University of Chinese Medicine, Guangzhou, China

³Department of Rehabilitation Center, First Affiliated Hospital of Guangzhou

University of Chinese Medicine, Guangzhou, China

Corresponding author

Professor Rong Li

Email: 256298797@qq.com

Tel: 020-36591357

Present address

Guangzhou University of Chinese Medicine, No. 12, Ji Chang Road, Baiyun District,

Guangzhou 510405, China

ABSTRACT

 Introduction: Coronary heart disease (CHD) is the most common cause of death worldwide. Percutaneous coronary intervention (PCI) has been shown to reduce mortality in patients with CHD. However, there are still recurrences of cardiovascular events after PCI. Cardiac rehabilitation (CR) in patients with established CHD is associated with reductions in cardiovascular mortality and hospital admissions, as well as improved quality of life. More and more clinical trials suggest that traditional Chinese exercise (TCE) plays a positive role in patients post-PCI. The primary purposes of the current study are to conduct a network meta-analysis of randomized trials to determine the effects of TCE in patients after PCI, and to separately compare the effects of tai chi, baduanjin and yijinjing on cardiac rehabilitation after PCI.

Methods and analysis: Studies will be retrieved from the following databases: PubMed, Embase, Cochrane Library, Chinese National Knowledge Infrastructure, Wanfang Data, Chinese BioMedical Database and Chinese Science and Technology Periodicals Database, from inception to December 2018. We will include RCTs that are related to the effects of TCE therapies in patients after PCI. The primary outcomes will be all-cause mortality, revascularisations, health-related quality of life (HRQL), and hospitalisations. Two reviewers will independently select eligible articles. For each included article, two reviewers will independently extract the data and assess the risk of bias by using the Cochrane risk of bias tool. Bayesian network meta-analyses will be conducted to pool all treatment effects. The ranking probabilities for the optimal intervention of various treatments (tai chi, baduanjin or yijinjing) will be estimated by the mean ranks and surface under the cumulative ranking curve (SUCRA). The Grading of Recommendations Assessment, Development and Evaluation System will be utilized to assess the quality of evidence.

Ethics and dissemination: The results will be disseminated through peer-reviewed publications. They will provide consolidated evidence to inform clinicians on the potential functions of TCE in CR, and to provide reliable evidence for the application of TCE.

Trial registration number: CRD42018088415

Strengths and limitations of this study

- This is the first systematic review to use network meta-analysis to compare various forms of traditional Chinese exercise.
- This is the first systematic review to compare the effects of baduanjin, yijinjing and tai chi on cardiac rehabilitation post-PCI.
- This study will assess the effects of TCEs and their safety regarding cardiac rehabilitation after PCI.
- The study will use the Grading of Recommendations Assessment, Development and Evaluation System to further assess the quality of the evidence.
- Due to the changes in the frequency and duration of treatment, there may be methodological heterogeneity.

INTRODUCTION

Description of the condition

Coronary heart disease (CHD), also known as coronary artery disease (CAD), is the most common cause of death worldwide, causing 7.4 million deaths in 2013, accounting for one-third of all deaths globally (WHO 2014)¹. In addition to the requisite medical therapy, mechanical revascularization with coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) is needed for patients with CHD. PCI has been shown to reduce mortality in patients with CHD². During follow-up, however, the benefits of PCI surgery still carry significant risks of coronary spasm, endothelial cell injury, recurrent ischemia, and even restenosis or thrombus³⁻⁵. Numerous guidelines endorse the benefits of cardiac rehabilitation (CR), which is recommended for patients with chronic stable angina, acute coronary syndromes or for patients post-PCI surgery^{2,6-10}. Combined with routine therapy, exercise-based CR, which has been recommended by American Heart Association (AHA) guidelines¹¹, is a safe option. It has been reported that light to moderate intensity physical activity can reduce coronary heart disease mortality¹². Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

Description of the intervention

For centuries, traditional Chinese exercise (TCE) (Figure 1), a series of mind-body exercises including baduanjin, yijinjing, and tai chi (TC, also known as

'taiji chuan'), has been widely practiced in China for both preventive and therapeutic purposes. Based on the theoretical principles of traditional Chinese medicine (TCM), in clinical rehabilitation focuses on posture, meditation, and coordination of breath. The common characteristics of these movements is that they are slow, relaxing and systematic, and therefore suitable for physically weak patients. By correcting body posture and movements, adjusting breathing patterns, and maintaining stillness of mind, a wide array of natural self-regulatory/self-healing mechanisms can be activated to stimulate the balanced release of endogenous neurohormones¹³⁻¹⁴. Considered to be a low-risk, promising intervention that is used widely in the prevention of cardiovascular disease, TCEs are easy to master in a short time and have few physical demands¹⁵. Regardless of previous exercise experience or aerobic capacity, the exercise intensity of TCE is suited for persons of all ages. Moreover, TCE requires no expensive equipment and can be performed either individually or in groups. Most existing systematic reviews have focused on specific forms of TCE, such as tai chi or baduanjin¹⁶⁻¹⁸. Whether TCE has positive clinical effects on patients with CHD after PCI, however, remains unclear.

Therefore, we will conduct the present network meta-analysis to explore whether TCE affects the primary endpoint events of cardiac death, recurrence of MI, repeated PCI, and restenosis after PCI; to determine whether TCE could be an effective method for improving secondary endpoint measures such as quality of life (QoL), physical functions and symptoms, after PCI; to separately compare the effects of Tai chi, Baduanjin and Yijinjing on patients post-PCI. (Figure 2)

METHODS AND ANALYSIS

Registration

 This protocol has been developed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement. It has also been registered with the International Prospective Register of Systematic Reviews (registration number CRD42018088415).¹⁹

Eligibility criteria

Study type

BMJ Open

We will include randomised controlled trials that compare the effects of three different traditional Chinese exercise therapies (Tai chi, Baduanjin and Yijinjing) with a no exercise control on patients with CHD following PCI. The following study designs or publication types will be excluded: (1) non-clinical research literature, such as animal experiments, reviews or case reports; (2) duplicate publications; (3) literature with incomplete data, the study of chaos; (4) studies which lack primary outcome measures. If multiple intervention data can be obtained, the trails can be adopted. If data for comparison of multiple interventions cannot be directly obtained, we will try E-mailing the corresponding author to obtain the original data. If the data cannot be obtained, the trails will also be excluded.

Participants

This network-analysis will include patients with coronary heart disease who have received TCE intervention after PCI.

Interventions

We plan to include the following TCE therapies: tai chi, baduanjin and yijinjing, and patients who have received TCE interventions either alone or in combination with appropriate training. For comparisons, both active (e.g. walking) or non-active (e.g. usual care) controls compared with TCEs will be included. For the reason that some RCTs set a placebo controlled arm as the comparator, information about interventions from placebo controlled trails will also be extracted.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Outcomes

The primary outcomes will include: (1) all-cause mortality; (2) revascularisations (CABG or PTCA); (3)results of Medical Outcome Study (MOS) 36-Item Short-Form Health Survey (SF-36); (4) hospitalisations: hospital readmission dates.

The secondary outcomes will include: (1) b-type natriuretic peptide ; (2) blood lipid indexes (i.e. serum total cholesterol, triglyceride , low density lipoprotein cholesterol and high-density lipoprotein cholesterol); (3) echocardiography; (4) adverse events.

Search strategy

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Data collection process

All titles and abstracts of potential trials will be retrieved and organised by two authors (Weipeng Sun and Ting Li) in Endnote X7. Duplicate records will be excluded. The database will then be copied and provided to the first author for duplicate screening. Any disagreements between the two authors will be resolved by discussion with the whole team at a regular meeting. We will allocate the trials to the following five groups: inclusion group, non-patient group, intervention group, outcome group and awaiting group. For this project, Microsoft Excel will be used for preliminary data collection. Four spreadsheets including general information (i.e. author list, publication year, and journal, etc), characteristics of the included trials (i.e. diagnostic criteria, age range, study drugs, and dose range, etc), risk of bias assessed using the Cochrane risk of bias assessment tool¹⁹ and outcome data extraction (i.e. numbers of response events and non-response events, time points, mean or mean difference, reported outcome definitions, summary data related to treatment effects, etc.), will be represented in the table. Relevant original data will be submitted as attachments.

BMJ Open

We will express the study selection and data colletion process with a PRISMA flow chart (http://www.prisma-statement.org) (Figure 3).

Quality assessment

The methodological quality of the eligible studies, concealment allocation, covering randomisation, blinding and other biases will be evaluated by two authors (Tian Zhang, Xiaoqi Zhou) according to the Cochrane risk of bias assessment tool ²⁰. Particular attention will be paid to the adequacy of random allocation concealment and blinding due to the potential failure of inadequate concealment in the randomisation test. Considering the diagnostic criteria, the sample size calculation method, reporting of withdrawals and follow-up, any other sources of bias will be cautiously assessed. The complete assessment procedures are as follows²¹: (1) offer direct and indirect effect estimates; (2) assess the quality of direct and indirect estimates; (3) present the results of the network meta-analysis; (4) assess the quality of the network meta-analysis effect estimates.

Dealing with missing data

We will initially contact both senior and/or corresponding author to obtain any missing data. If no one responds, the following approaches will be used to estimate the missing data. Instead of providing the mean and SD, the number of responding patients employing a validated imputation method will be calculated for studies failing to report the patients' numbers after treatment. We will also try to estimate from graphs if possible. The reason for exclusion of the available data will be reported.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Network meta-analysis

We will use the Markov Chain Monte Carlo algorithm (MCMC) by applying WinBUGS 1.4.3 to conduct the network meta-analysis (NMA) in a Bayesian hierarchical framework. The inverse variance heterogeneity method will be used in order to overcome the limitations of the fixed and random effects models. Minimally informative prior distributions will be used for the main outcome. The magnitude of heterogeneity variance will be used to investigate the statistical heterogeneity of all of the NMAs. If direct evidence is feasible, NMAs will be evaluated comprehensively. In

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

treatment effect assessed by indirect and direct comparisons, the potential difference can be evaluated by several methods, and 95% CIs and z-a values will be calculated for each outcome from each study. The antilogy of the model will be explored by using the node-splitting method, which generates a p-value for the difference between direct and indirect estimates in each closed loop in the network (p-values of <0.05 indicate the presence of inconsistency between direct and indirect estimates in a particular closed loop). We will use the deviance information criterion (DIC) to compare the random and fixed effects models to evaluate model fitness by taking references from the guidelines commonly used in the analogous Akaike Information Criteria: values which decrease by at least 10 points indicate significantly better model fit and parsimony. The mean ranks and surface under the cumulative ranking curve (SUCRA) will be used to sequence the probabilities of the optimal intervention of various treatments. We will describe SUCRA with percentages. For the treatment, better ranks are indicated by higher values. Stata 12 will be used to generate result figures and NMA graphs. If the data cannot be used for quantitative analysis, the evidence will be described and summarised.

Sensitivity analysis and subgroup analysis

The strategies can be used to address the problem of heterogeneity of pairwise meta-analysis, as well as be employed to tackle incongruity of network analysis. Inconsistent sources will be explored by performing a network meta-regression. We will conduct a sensitivity analysis to explore the strong conclusions of the main results wherever practical. The overall results will be influenced because the methodological quality levels of the studies vary. Sensitivity analysis will be conducted to exclude trials with small sample sizes (i.e. arms of less than 10 patients) and remove trails that report the generation of non-random sequences. It is planned (if the number of trials is high enough) to perform sensitivity analysis with respect to age difference and geographical region.

Publication bias

If feasible, we will also convey any small study effects that exist within a network of interventions. Publication bias will be assessed by performing Egger's

BMJ Open

regression test. If feasible, a statistical model will be used to convey the network of interventions, including small study effects.

Quality of evidence

For the main outcomes, two authors (Xiaojiang Yu, Wei Wu) will assess the quality of evidence based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE), covering study limitations, inconsistency, indirectness, imprecision and publication bias. Five factors, including the limitations of research design, indirectness, incongruity, imprecision and publication bias, will be investigated.

Patient and Public Involvement

Patients and public will not be involved.

DISCUSSION

Previous reviews have indicated that left ventricular (LV) remodeling after myocardial infarction (MI) can be reduced by baduanjin; Another study demonstrated that baduanjin provides clinically meaningful improvement for SBP, DBP, BMI, blood glucose, TG, HDL-C, LDL-C and QoL²². Research on TC has discovered that it can improve VO₂ max in patients with coronary disease. This suggests that TC could be applied in cardiac rehabilitation (CR) as an adjuvant therapy²³; Another study has indicated that TC might improve 6-MWD, QoL, and LVEF in patients, and could be associated with significant reductions in BNP and HR²⁴. This would signify the clinical importance of CR post-PCI. Research has also shown that the effects of TCE on blood pressure and blood lipids commonly acknowledged as the primary targets for cardiovascular risk reduction (e.g. LDL-C) are clinically significant²⁵.

TCE could therefore be used in CR therapy post-PCI, but its efficacy and mechanisms remain unclear. More larger-scale well-designed studies using standardized training protocols are needed in order for specific and accurate conclusions to be made. Thus, the aim of the present study is to systematically assess the effects of TCE on patients in CR post-PCI by using enough studies to ensure adequate power for the meta-analysis. To the best of our knowledge, this review will

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

be the first network meta-analysis to evaluate the impact of TCE for patients in CR post-PCI. We hope the results of this review will help establish a better approach for exploring the potential functions of TCE in CR and will also provide reliable evidence supporting the use of TCE.

Ethics and dissemination: The results will be disseminated through peer-reviewed publications. They will provide consolidated evidence to inform clinicians on the potential functions of TCE in CR, and to provide reliable evidence for the application of TCE.

Contributors

CL and RL conceived of the study and drafted the protocol. JW, WS and XZ revised it. TL, WW and XY developed the search strategies and conducted data collection. TZ analysed the data independently. All authors have approved the final manuscript.

Funding

This study is supported by the 2017 Diagnosis and Treatment Innovation Project at The First Affiliated Hospital of Guangzhou University of Chinese Medicine.

Competing interests

None declared.

Provenance and peer review

Not commissioned; externally peer reviewed.

Data sharing statement

No additional data are available.

Consent for the pictured individual

The individual in Figure 1 has provided informed written consent for the publication of their image.

Reference:

[1] Claire T, Costas T, James M, et al. Submaximal fitness and mortality risk reduction in coronary heart disease: a retrospective cohort study of community-based exercise rehabilitation:[J]. Bmj Open, 2016, 6(6):e011125.

[2] Levine G N, Bates E R, Blankenship J C, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.[J]. Circulation, 2011, 124(23):2574-609.

[3] Zhang Y, Ma X J, Shi D Z. Effect of Trimetazidine in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis[J]. Plos One, 2015, 10(9):e0137775.

[4] Dzavik V, Ghali WA, Norris C, Mitchell LB, et al. Long-term survival in 11,661 patients with multivessel coronary artery disease in the era of stenting: a report from the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators. American HeartJournal. 2001;142(1):119-126
[5] Kastrati A, Pache J, Dirschinger J, Neumann FJ, et al. Primary intracoronary stenting in acute myocardial infarction: long-term clinical and angiographic follow-up and risk factor analysis. AmericanHeart Journal. 2000;139(1):208-216.
[6] Perk J, De BG, Gohlke H, Graham I, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012) : the fifth joint task force of the

European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted byre. European Journal of Preventive Cardiology. 2012;19(4):403-488.

[7] Thomas RJ, King M, Lui K, Oldridge N, et al. AACVPR/ACC/AHA 2007 performance measures oncardiac rehabilitation for referral to and delivery of cardiac rehabilitation/secondary preventionservices endorsed by the American College of Chest Physicians, American College of Sports Medicine, American Phys. Journal of the American College of Cardiology. 2007;50(14):1400-1433. [8] Anderson JL, Adams CD, Antman EM, Bridges CR, et al. ACC/AHA 2007

 Guidelines for the Management of Patients With Unstable Angina/Non -

ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology. 2007;50(7):e148.

[9] Leon Arthur S,Franklin Barry A,Costa Fernando et al. Cardiac rehabilitation and secondary prevention of coronary heart disease: an American Heart Association scientific statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity), in collaboration with the American association of Cardiovascular and Pulmonary Rehabilitation.[J] .Circulation, 2005, 111(3): 369-76.

[10] Eagle Kim A,Guyton Robert A, Davidoff Ravin et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery).[J] .J. Am. Coll. Cardiol., 2004, 44(5): e213-310.

[11] Fletcher GF, Ades PA, Kligfield P, Arena R, et al. Exercise standards for testing and training: a scientific statement from the American Heart Association. Circulation. 2013;128(8):873.

[12] Leon AS, Connett J, Jr JD, Rauramaa R. Leisure-time physical activity levels and risk of coronary heart disease and death. The Multiple Risk Factor Intervention Trial. Jama. 1987;258(17):2388-2395.

[13] Wang XQ, Pi YL, Chen PJ, Yu L, et al. Traditional Chinese Exercise for Cardiovascular Diseases:Systematic Review and Meta - Analysis of Randomized Controlled Trials. Journal of the American Heart Association Cardiovascular & Cerebrovascular Disease. 2016;5(3):e2562.

[14] Jahnke Roger, Larkey Linda, Rogers Carol et al. A comprehensive review of health benefits of qigong and tai chi.[J] .Am J Health Promot, 2010, 24(6): e1-e25.

BMJ Open

r
Z
3
4
5
5
6
7
0
0
9
10
11
11
12
13
14
14
15
16
17
17
18
19
20
20
21
22
23
23
24
25
26
20
27
28
29
20
30
31
32
22
33
34
35
22
36
37
38
50
39
40
41
40
42
43
44
Λ <i>Γ</i>
45
46
47
10
48
49
50
50 E 1
21
52
53
5.5 E 4
54
55
56
50
5/
58
59
60
60

[15] Chan CL, Wang CW, Ho RT, Ho AH, et al. A systematic review of the effectiveness of qigong exercise in cardiac rehabilitation. American Journal of Chinese Medicine. 2012;40(2):255-267.

[16] Ding M. Tai Chi for stroke rehabilitation: a focused review. American Journal of Physical Medicine & Rehabilitation. 2012;91(12):1091.

[17] Dalusungangosta A. The impact of Tai Chi exercise on coronary heart disease: a systematic review. Journal of the American Academy of Nurse Practitioners.

2011;23(7):376.

[18] Yeh GY, Wang C, Wayne PM, Phillips R. Tai chi exercise for patients with cardiovascular conditions and risk factors: A SYSTEMATIC REVIEW. Journal of Cardiopulmonary Rehabilitation & Prevention. 2009;29(3):152.

[19] Shamseer Larissa, Moher David, Clarke Mike et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation.[J] .BMJ, 2015, 350: g7647..

[20] Savovic J, Page M, Elbers R, Hrobjartsson A, et al. A revised tool for assessing risk of bias in randomized trials (RoB 2.0). TRIALS. 2017;181.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

[21] Salanti G, Del GC, Chaimani A, Caldwell DM, Higgins JP. Evaluating the quality of evidence from anetwork meta-analysis. Plos One. 2014;17(7):A324.

[22] Mao S, Zhang X, Shao B, Hu X, et al. Baduanjin Exercise Prevents

post-Myocardial Infarction LeftVentricular Remodeling (BE-PREMIER trial): Design

and Rationale of a Pragmatic Randomized Controlled Trial. Cardiovascular Drugs & Therapy. 2016;30(3):315.

[23] Xiong X, Wang P, Li S, Zhang Y, Li X. Effect of Baduanjin exercise for hypertension: A systematic review and meta-analysis of randomized controlled trials. Maturitas. 2015;80(4):370-378.

[24] Yang YL, Wang YH, Wang SR, Shi PS, Wang C. The Effect of Tai Chi on Cardiorespiratory Fitness for Coronary Disease Rehabilitation: A Systematic Review and Meta-Analysis. Frontiers in Physiology.2017;8:1091.

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

[25] Ren X, Li Y, Yang X, Li J, et al. The Effects of Tai Chi Training in Patients with Heart Failure: A Systematic Review and Meta-Analysis. Frontiers in Physiology.2017;8:989

No.	Search terms
1	Tai Ji Quan
2	Tai chi
3	Tai ji
4	Taijiquan
5	Baduanjin
6	Baduanjin exercise
7	eight section brocades
8	Yi Jinjing
9	Yijinjing
10	Yijinjing exercise
11	or1-10
12	Coronary Heart Diseases
13	CHD
14	Coronary artery atherosclerosis heart disease
15	Acute coronary syndrome

16	ACS
17	Acute myocardial infarction
18	AMI
19	Heart failure
20	HF
21	Cardiovascular events
22	percutaneous coronary intervention
23	PCI
24	or12-23
25	11 and 24

Figure 1. Traditional Chinese exercise (A is Tai chi, B is Baduanjin, C is Yi Jinjing), and the pictured individual has provided consent for publication of their image.

Figure 2. Network plot of all possible direct comparisons between the eligible interventions.

Figure 3. Flow diagram of the study selection process.



175x175mm (300 x 300 DPI)

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml





PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

Section and topic	Item No	Checklist item	Reported on page #
ADMINISTRATIVE	INFOR	RMATION	
Title:			
Identification	1a	Identify the report as a protocol of a systematic review	1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	no
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	3
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	14
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	no
Support:			
Sources	5a	Indicate sources of financial or other support for the review	14
Sponsor	5b	Provide name for the review funder and/or sponsor	14
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	14
INTRODUCTION			
Rationale	6	Describe the rationale for the review in the context of what is already known	4-6
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	2-3
METHODS			
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	6-7
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	6
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	7-8

Study records:			
Data	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	7
management			
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	8
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	8,9
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre- planned data assumptions and simplifications	8-10
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	7
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	11,12
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	10,11
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I^2 , Kendall's τ)	10-12
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	11,12
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	11,12
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	12
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	12
* It is strongly rocomm	iended	that this checklist be read in conjunction with the PKISMA-P Explanation and Elaboration (cite when ava condiments to a review protocol should be treaked and dated. The convright for PDISMA P (including above	allable) for important